Intervention

Remibrutinib

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting1

Common conditions3

Lead sponsors shown2

Clinical trials

4 shown

Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.NCT07758270 · 2026-08-15

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)NCT05147220 · 2021-12-16

ACTIVE_NOT_RECRUITING

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)NCT05156281 · 2021-12-13

ACTIVE_NOT_RECRUITING

A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's SyndromeNCT04035668 · 2019-07-12

Common conditions

Relapsing Multiple Sclerosis2 Multiple Sclerosis (MS) - Relapsing-remitting1 Sjögren Syndrome1

Leading sponsors

Novartis Pharmaceuticals3 Washington University School of Medicine1

Trial status mix

ACTIVE_NOT_RECRUITING2

RECRUITING1

TERMINATED1

Phase mix

PHASE32

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.